Compare CETY & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CETY | GDTC |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6M | 10.4M |
| IPO Year | 2020 | 2021 |
| Metric | CETY | GDTC |
|---|---|---|
| Price | $0.97 | $0.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.0K | ★ 16.4K |
| Earning Date | 11-18-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $957,633.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.46 | $0.68 |
| 52 Week High | $3.05 | $3.68 |
| Indicator | CETY | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 49.29 | 47.73 |
| Support Level | $0.69 | $0.74 |
| Resistance Level | $1.03 | $1.07 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 38.89 | 38.53 |
Clean Energy Technologies Inc develop renewable energy products and solutions and establish partnerships in renewable energy that make environmental and economic sense. Its segments are Waste Heat Recovery Solutions - It recycle wasted heat produced in manufacturing, waste to energy and power generation. Waste to Energy Solutions - It convert waste products created in manufacturing, agriculture, wastewater treatment plants and other industries to electricity, renewable natural gas hydrogen and bio char. Engineering, Consulting and Project Management Solutions - It provide power generation, waste to energy, and heat recovery, Procurement and Construction (EPC) services to municipal and industrial customers. It generates majority of revenue from United States followed by International.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.